An Integrated Systematic Analysis and the Clinical Significance of Hepcidin in Common Malignancies of the Male Genitourinary System

Tumors of the male genitourinary system are of great concern to the health of men worldwide. Although emerging experiment-based evidence indicates an association between hepcidin and such cancers, an integrated analysis is still lacking. For this reason, in this study, we determined the underlying oncogenic functions of hepcidin in common male genitourinary system tumors, including bladder urothelial carcinoma (BLCA), kidney chromophobe (KICH), kidney renal clear cell carcinoma (KIRC), kidney renal papillary cell carcinoma (KIRP), prostate adenocarcinoma (PRAD), and testicular germ cell tumors (TGCT) according to the data from The Cancer Genome Atlas. We found that hepcidin was highly expressed in kidney and testicular cancers. Meanwhile, the expression level of hepcidin was distinctly associated with the prognosis and immune cell infiltration in male patients with certain genitourinary system cancers, especially in KIRC. Elevated hepcidin levels also present as a risk factor in male genitourinary system tumors. Moreover, enrichment analyses revealed that some of the principal associated signaling pathways involving hepcidin and its related genes are identified as tumorigenesis-related. Immunofluorescence staining confirmed the conclusion of our immune infiltration analysis in KIRC tissue. In this study, for the first time, we provided evidence for the oncogenic function of hepcidin in different types of male genitourinary system tumors.

[1]  A. Jemal,et al.  Annual Report to the Nation on the Status of Cancer, Part 1: National Cancer Statistics , 2021, Journal of the National Cancer Institute.

[2]  Colorectal Cancer Cells Ectopically Express Hepcidin to Sequester Iron. , 2021, Cancer discovery.

[3]  Ho-Joon Lee,et al.  Hepcidin sequesters iron to sustain nucleotide metabolism and mitochondrial function in colorectal cancer epithelial cells. , 2021, Nature Metabolism.

[4]  J. Ferlay,et al.  Cancer statistics for the year 2020: An overview , 2021, International journal of cancer.

[5]  Yumei Fan,et al.  Hepcidin Upregulation in Lung Cancer: A Potential Therapeutic Target Associated With Immune Infiltration , 2021, Frontiers in Immunology.

[6]  V. N. Blindar,et al.  The role of interleukin-6 and hepcidin 25 in the pathogenesis of anemic syndrome associated with malignant neoplasms with breast cancer patients before neoadjuvant chemotherapy. , 2021, Klinicheskaia laboratornaia diagnostika.

[7]  F. Costanzo,et al.  Iron Metabolism in the Tumor Microenvironment—Implications for Anti-Cancer Immune Response , 2021, Cells.

[8]  A. Jemal,et al.  Cancer Statistics, 2021 , 2021, CA: a cancer journal for clinicians.

[9]  Weiwei Zhou,et al.  SurvivalMeth: a web server to investigate the effect of DNA methylation-related functional elements on prognosis , 2020, Briefings Bioinform..

[10]  P. Porporato,et al.  Iron: An Essential Element of Cancer Metabolism , 2020, Cells.

[11]  Iron Dysregulation in Human Cancer: Altered Metabolism, Biomarkers for Diagnosis, Prognosis, Monitoring and Rationale for Therapy , 2020, Cancers.

[12]  Abeer A Mokhtar,et al.  Circulating osteocyte‐related biomarkers (vitamin D, sclerostin, dickkopf-1), hepcidin, and oxidative stress markers in early breast cancer: Their impact in disease progression and outcome , 2020, The Journal of Steroid Biochemistry and Molecular Biology.

[13]  Tewodros Shibabaw,et al.  Inflammation Mediated Hepcidin-Ferroportin Pathway and Its Therapeutic Window in Breast Cancer , 2020, Breast cancer.

[14]  T. Ganz,et al.  Prognostic associations of plasma hepcidin in women with early breast cancer , 2020, Breast Cancer Research and Treatment.

[15]  A. Elia,et al.  Iron Induces Cell Death and Strengthens the Efficacy of Antiandrogen Therapy in Prostate Cancer Models , 2020, Clinical Cancer Research.

[16]  Xiaole Shirley Liu,et al.  TIMER2.0 for analysis of tumor-infiltrating immune cells , 2020, Nucleic Acids Res..

[17]  J. Saurin,et al.  Iron and hepcidin mediate human colorectal cancer cell growth. , 2020, Chemico-biological interactions.

[18]  Zhen Cheng,et al.  Expression of serum BMP6 and hepcidin in cancer-related anemia , 2020, Hematology.

[19]  W. Linehan,et al.  The Cancer Genome Atlas of renal cell carcinoma: findings and clinical implications , 2019, Nature Reviews Urology.

[20]  S. Liu,et al.  Changes of Hepcidin levels and their correlation with interleukin-6 and C-reactive protein in liver cancer patients with chronic inflammatory anemia. , 2019, Journal of biological regulators and homeostatic agents.

[21]  Jana Jeschke,et al.  MEXPRESS update 2019 , 2019, Nucleic Acids Res..

[22]  Zemin Zhang,et al.  GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis , 2019, Nucleic Acids Res..

[23]  J. Onuchic,et al.  NEET Proteins: A New Link Between Iron Metabolism, Reactive Oxygen Species, and Cancer. , 2018, Antioxidants & redox signaling.

[24]  E. Bonanno,et al.  New highlight in breast cancer development: the key role of hepcidin and iron metabolism. , 2018, Annals of translational medicine.

[25]  Chen Hu,et al.  Role of hepcidin and iron metabolism in the onset of prostate cancer. , 2018, Oncology letters.

[26]  H. Eguchi,et al.  Association of iron metabolic enzyme hepcidin expression levels with the prognosis of patients with pancreatic cancer. , 2018, Oncology letters.

[27]  Steven J. M. Jones,et al.  Oncogenic Signaling Pathways in The Cancer Genome Atlas. , 2018, Cell.

[28]  F. Torti,et al.  Contribution of three dimensional architecture and tumor-associated fibroblasts to hepcidin regulation in breast cancer , 2018, Oncogene.

[29]  J. Vilo,et al.  MethSurv: a web tool to perform multivariable survival analysis using DNA methylation data. , 2018, Epigenomics.

[30]  D. Girelli,et al.  Hepcidin and DNA promoter methylation in hepatocellular carcinoma , 2018, European journal of clinical investigation.

[31]  R. Muschel,et al.  A core matrisome gene signature predicts cancer outcome , 2018, British Journal of Cancer.

[32]  Jun S. Liu,et al.  TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells. , 2017, Cancer research.

[33]  Longqiang Liu,et al.  Hepcidin and iron metabolism in the pathogenesis of prostate cancer. , 2017, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

[34]  A. Tjønneland,et al.  Hepcidin levels and gastric cancer risk in the EPIC‐EurGast study , 2017, International journal of cancer.

[35]  Chad J. Creighton,et al.  UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses , 2017, Neoplasia.

[36]  Jun S. Liu,et al.  TIMER : AWeb Server for Comprehensive Analysis of Tumor-In fi ltrating Immune Cells , 2017 .

[37]  Jana Jeschke,et al.  MEXPRESS: visualizing expression, DNA methylation and clinical TCGA data , 2015, BMC Genomics.

[38]  L. Miller,et al.  Hepcidin regulation in prostate and its disruption in prostate cancer. , 2015, Cancer research.

[39]  Subha Madhavan,et al.  The CPTAC Data Portal: A Resource for Cancer Proteomics Research. , 2015, Journal of proteome research.

[40]  K. Tomczak,et al.  The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge , 2015, Contemporary oncology.

[41]  Philippe Bardou,et al.  jvenn: an interactive Venn diagram viewer , 2014, BMC Bioinformatics.

[42]  P. Arosio.  New signaling pathways for hepcidin regulation. , 2014, Blood.

[43]  F. Roche,et al.  Unbiased RNAi screen for hepcidin regulators links hepcidin suppression to proliferative Ras/RAF and nutrient-dependent mTOR signaling. , 2014, Blood.

[44]  F. Yu,et al.  Roles of the hepcidin–ferroportin axis and iron in cancer , 2014, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[45]  F. Yu,et al.  Increased hepcidin expression in non‐small cell lung cancer tissue and serum is associated with clinical stage , 2014, Thoracic cancer.

[46]  Benjamin E. Gross,et al.  Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.

[47]  D. Swinkels,et al.  Hepcidin in human iron disorders: diagnostic implications. , 2011, Clinical chemistry.

[48]  M. Farag,et al.  Hepcidin mRNA level as a parameter of disease progression in chronic hepatitis C and hepatocellular carcinoma. , 2009, Journal of the Egyptian National Cancer Institute.

[49]  J. Kaplan,et al.  A new wrinkle in the fold: hepcidin links inflammation to the unfolded protein response. , 2009, Cell metabolism.

[50]  M. Rodnina,et al.  Kinetic checkpoint at a late step in translation initiation. , 2008, Molecular cell.

[51]  B. Lönnerdal,et al.  Hepcidin, the recently identified peptide that appears to regulate iron absorption. , 2004, The Journal of nutrition.

[52]  Tomas Ganz,et al.  Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. , 2003, Blood.

[53]  Brad T. Sherman,et al.  DAVID: Database for Annotation, Visualization, and Integrated Discovery , 2003, Genome Biology.

[54]  Bruno Turlin,et al.  A New Mouse Liver-specific Gene, Encoding a Protein Homologous to Human Antimicrobial Peptide Hepcidin, Is Overexpressed during Iron Overload* , 2001, The Journal of Biological Chemistry.

[55]  J. Alberta,et al.  Identification of an activity that interacts with the 3'-untranslated region of c-myc mRNA and the role of its target sequence in mediating rapid mRNA degradation. , 1994, The Journal of biological chemistry.

[56]  M. C. Ganoza,et al.  Potential secondary structure at translation-initiation sites [published erratum appears in Nucleic Acids Res 1988 May 11;16(9): 4196] , 1987, Nucleic Acids Res..

[57]  B. Beutler,et al.  Identification of a common nucleotide sequence in the 3'-untranslated region of mRNA molecules specifying inflammatory mediators. , 1986, Proceedings of the National Academy of Sciences of the United States of America.